Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Microbiology

Vol 9 No 2 (2024): December

Effect the Nanoparticles of Fe2O3 and CuO to Increasing the Activity of Sulfadiazine Against Multidrug Resistant Pseudomonas Aeruginosa
Pengaruh Nanopartikel Fe2O3 dan CuO untuk Meningkatkan Aktivitas Sulfadiazin Terhadap Pseudomonas Aeruginosa yang Resisten Terhadap Berbagai Jenis Obat



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.9902
Published
August 26, 2024

Abstract

General Background: Antibiotic resistance is a critical global health issue, and innovative approaches are needed to combat multidrug-resistant (MDR) bacteria. Specific Background: Nanotechnology has emerged as a promising strategy to enhance antibiotic efficacy and reduce resistance. Knowledge Gap: However, there is limited understanding of how metal oxide nanoparticles (NPs) like Fe2O3 and CuO can be utilized to improve the performance of antibiotics such as sulfadiazine. Aims: This study aimed to synthesize Fe2O3 and CuO nanoparticles, conjugate them with sulfadiazine, and evaluate their antibacterial efficacy against MDR Pseudomonas aeruginosa. Results: The nanoparticles were synthesized via chemical precipitation, with Fe2O3 and CuO having mean crystal sizes of 41.40 nm and 44.83 nm, respectively. When bound to sulfadiazine, the crystal sizes were 42.62 nm (Fe2O3) and 38.77 nm (CuO). The minimum inhibitory concentration (MIC) values for sulfadiazine-bound CuO and Fe2O3 NPs ranged from 16-32 μg/ml, significantly lower than the 64-128 μg/ml observed for standard sulfadiazine. Hemolysis assays confirmed the biocompatibility of these nanocomposites at tested concentrations. Novelty: The study reveals that Fe2O3 and CuO nanoparticles significantly enhance sulfadiazine's antibacterial activity against MDR P. aeruginosa, suggesting a potential method to bypass traditional resistance mechanisms. Implications: The study suggests that nanoparticle-conjugated antibiotics could be a promising solution for combating antibiotic resistance, potentially reducing its negative impact on public health.

Highlights:

 

  1. Nanoparticles reduce sulfadiazine's MIC against MDR Pseudomonas aeruginosa.
  2. Fe2O3 and CuO nanoparticles enhance antibiotic efficacy.
  3. Hemolysis assays confirm nanocomposites' safety and biocompatibility.

 

Keywords: Nanotechnology, Antibiotic Resistance, Fe2O3 Nanoparticles, CuO Nanoparticles, MDR Pseudomonas aeruginosa

References

  1. . C. Llor and L. Bjerrum, "Antimicrobial Resistance: Risk Associated with Antibiotic Overuse and Initiatives to Reduce the Problem," Therapeutic Advances in Drug Safety, vol. 5, pp. 229–241, 2014.
  2. . U. Desselberger, "Emerging and Re-Emerging Infectious Diseases," Journal of Infection, vol. 40, pp. 3–15, 2000.
  3. . B. Li and T. J. Webster, "Bacteria Antibiotic Resistance: New Challenges and Opportunities for Implant-Associated Orthopedic Infections," Journal of Orthopaedic Research, vol. 36, pp. 22–32, 2018.
  4. . C. L. Ventola, "The Antibiotic Resistance Crisis: Part 1: Causes and Threats," Pharmacy and Therapeutics, vol. 40, p. 277, 2015.
  5. . X. Yang, W. Ye, Y. Qi, Y. Ying, and Z. Xia, "Overcoming Multidrug Resistance in Bacteria Through Antibiotics Delivery in Surface-Engineered Nano-Cargos: Recent Developments for Future Nano-Antibiotics," Frontiers in Bioengineering and Biotechnology, vol. 9, p. 696514, 2021.
  6. . P. Pachori, R. Gothalwal, and P. Gandhi, "Emergence of Antibiotic Resistance in Pseudomonas aeruginosa in Intensive Care Units: A Critical Review," Genes & Diseases, vol. 6, pp. 109–119, 2019.
  7. . A. P. Magiorakos et al., "Multidrug-Resistant, Extensively Drug-Resistant, and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance," Clinical Microbiology and Infection, vol. 18, pp. 268–281, 2012.
  8. . J. P. Horcajada et al., "Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections," Clinical Microbiology Reviews, vol. 32, pp. e19–e31, 2019.
  9. . S. Silver, L. T. Phung, and G. Silver, "Silver as Biocides in Burn and Wound Dressings and Bacterial Resistance to Silver Compounds," Journal of Industrial Microbiology and Biotechnology, vol. 33, no. 7, pp. 627–634, 2006.
  10. . H. S. Carr, T. J. Wlodkowski, and H. S. Rosenkranz, "Silver Sulfadiazine: In Vitro Antibacterial Activity," Antimicrobial Agents and Chemotherapy, vol. 4, no. 5, pp. 585–587, 1973.
  11. . T. Wlodkowski and H. Rosenkranz, "Antifungal Activity of Silver Sulphadiazine," The Lancet, vol. 302, no. 7831, pp. 739–740, 1973.
  12. . A. D. Russell and W. B. Hugo, "Antimicrobial Activity and Action of Silver," Progress in Medicinal Chemistry, vol. 31, pp. 351–370, 1994.
  13. . P. Dibrov, J. Dzioba, K. K. Gosink, and C. C. Häse, "Chemiosmotic Mechanism of Antimicrobial Activity of Ag+ in Vibrio cholerae," Antimicrobial Agents and Chemotherapy, vol. 46, no. 8, pp. 2668–2670, 2002.
  14. . K. B. Holt and A. J. Bard, "Interaction of Silver(I) Ions with the Respiratory Chain of Escherichia coli: An Electrochemical and Scanning Electrochemical Microscopy Study of the Antimicrobial Mechanism of Micromolar Ag+," Biochemistry, vol. 44, no. 39, pp. 13214–13223, 2005.
  15. . S. Begum, T. Begum, N. Rahman, and R. A. Khan, "A Review on Antibiotic Resistance and Ways of Combating Antimicrobial Resistance," GSC Biological and Pharmaceutical Sciences, vol. 14, no. 2, pp. 87–97, 2021.
  16. . L. Roth, M. Adler, T. Jain, and D. Bempong, "Monographs for Medicines on WHO’s Model List of Essential Medicines," Bulletin of the World Health Organization, vol. 96, no. 6, p. 378, 2018.
  17. . R. Jijie, A. Barras, F. Teodorescu, R. Boukherroub, and S. Szunerits, "Advancements on the Molecular Design of Nanoantibiotics: Current Level of Development and Future Challenges," Molecular Systems Design & Engineering, vol. 2, no. 4, pp. 349–369, 2017.
  18. . M. C. Roco, "Nanotechnology: Convergence with Modern Biology and Medicine," Current Opinion in Biotechnology, vol. 14, pp. 337–346, 2003.
  19. . Z. Ahmad, R. Pandey, S. Sharma, and G. Khuller, "Alginate Nanoparticles as Antituberculosis Drug Carriers: Formulation Development, Pharmacokinetics, and Therapeutic Potential," Indian Journal of Chest Diseases and Allied Sciences, vol. 48, p. 171, 2006.
  20. . A. Gupta, R. F. Landis, and V. M. Rotello, "Nanoparticle-Based Antimicrobials: Surface Functionality is Critical," F1000Research, vol. 5, p. 364, 2016.
  21. . M. J. Hajipour, K. Fromm, A. A. Ashkarran, and D. J. de Aberasturi, "Antibacterial Properties of Nanoparticles," Trends in Biotechnology, vol. 30, pp. 499–511, 2012.
  22. . N. V. Long et al., "Synthesis and Magnetism of Hierarchical Iron Oxide Particles," Materials & Design, vol. 86, pp. 797–808, 2015.
  23. . R. Jijie, A. Barras, F. Teodorescu, R. Boukherroub, and S. Szunerits, "Advancements on the Molecular Design of Nanoantibiotics: Current Level of Development and Future Challenges," Molecular Systems Design & Engineering, vol. 2, no. 4, pp. 349–369, 2017.
  24. . Clinical and Laboratory Standards Institute (CLSI), "Performance Standards for Antimicrobial Susceptibility Testing," 28th ed., Wayne, PA, USA, 2018.
  25. . X. Liu et al., "Silver Sulfadiazine Nanosuspension-Loaded Thermosensitive Hydrogel as a Topical Antibacterial Agent," International Journal of Nanomedicine, vol. 14, p. 289, 2019.
  26. . D. B. Alencar et al., "Antioxidant, Hemolytic, Antimicrobial, and Cytotoxic Activities of the Tropical Atlantic Marine Zoanthid Palythoa caribaeorum," Anais da Academia Brasileira de Ciencias, vol. 87, no. 2, pp. 1113–1123, 2015.

Downloads

Download data is not yet available.